```html

Westermark’s Sign (Pulmonary Embolism Indicator) – A Complete Medical Guide

Overview

Westermark’s sign is a radiographic finding on a chest X‑ray that suggests a pulmonary embolism (PE) – a blockage of one or more pulmonary arteries by a blood clot. The sign appears as a focal area of decreased vascular markings distal to an obstructed artery, reflecting reduced blood flow to that lung segment.

Who it affects: Westermark’s sign is not a disease itself; it is an indicator seen in patients who have a PE. Pulmonary embolism can occur at any age, but the incidence increases sharply after age 40 and peaks in the 60‑70‑year‑old range. Annually, PE accounts for roughly 60‑70 cases per 100,000 persons worldwide, making it a leading cause of cardiovascular death after myocardial infarction and stroke (CDC, 2022).

Prevalence of the sign: The classic Westermark’s sign is relatively uncommon—observed in only 2–4 % of chest radiographs taken for suspected PE (Radiology, 2017). Its rarity does not diminish its diagnostic importance; when present, it strongly points toward PE, especially when coupled with other clinical clues.

Symptoms

Because Westermark’s sign reflects an underlying PE, the symptom profile mirrors that of acute or sub‑acute pulmonary embolism.

• Shortness of breath (dyspnea): Sudden onset, often described as “air hunger.”
• Chest pain: Sharp, pleuritic pain that worsens with deep inspiration or coughing.
• Cough: May be dry or produce blood‑tinged sputum (hemoptysis) in larger emboli.
• Rapid heart rate (tachycardia): Typically >100 beats per minute.
• Rapid breathing (tachypnea): Respiratory rate >20 breaths per minute.
• Light‑headedness or syncope: Due to reduced cardiac output.
• Low‑grade fever: Occasionally present, especially in larger emboli.
• Leg swelling or pain: Indicates deep‑vein thrombosis (DVT), the most common source of emboli.

Symptoms can range from subtle (mild dyspnea) to catastrophic (sudden collapse). In elderly patients or those with comorbidities, classic chest pain may be absent, making imaging—where Westermark’s sign can be seen—especially valuable.

Causes and Risk Factors

Westermark’s sign results from a mechanical obstruction of pulmonary arterial flow. The obstruction is almost always a thrombus that has traveled from another vein, most commonly the deep veins of the lower extremities.

Primary causes

• Deep‑vein thrombosis (DVT): The leading source of emboli.
• Fat embolism: Usually after long‑bone fractures.
• Air embolism: Rare, often iatrogenic (e.g., diving accidents, central line placement).
• Amniotic fluid embolism: Seen in obstetric emergencies.
• Septic emboli: From infected heart valves or IV drug use.

Risk factors

• Prolonged immobility (e.g., long‑haul flights, postoperative bed rest).
• Recent major surgery or trauma, especially orthopedic procedures.
• Active cancer (especially pancreatic, lung, and ovarian) and chemotherapy.
• Hormonal therapy: oral contraceptives, hormone replacement, and pregnancy.
• Inherited or acquired hypercoagulable states (e.g., Factor V Leiden, antiphospholipid syndrome).
• Obesity (BMI ≥ 30 kg/m²) and sedentary lifestyle.
• Age > 60 years.
• History of prior DVT or PE.
• Chronic heart or lung disease that predisposes to venous stasis.

Understanding these factors helps clinicians decide when a chest X‑ray (and careful search for Westermark’s sign) is warranted.

Diagnosis

Westermark’s sign is identified on a standard postero‑anterior (PA) chest radiograph, but diagnosis of PE requires a multimodal approach.

Imaging studies

• Chest X‑ray: May show Westermark’s sign, Hampton’s hump, or be completely normal. Its primary role is to rule out alternative diagnoses.
• Computed tomography pulmonary angiography (CTPA): Gold‑standard imaging; visualizes intraluminal clots with >95 % sensitivity and >96 % specificity (Mayo Clinic, 2023).
• Ventilation‑Perfusion (V/Q) scan: Useful when contrast is contraindicated; a mismatch pattern supports PE.
• Doppler ultrasound of the legs: Detects DVT, the common embolic source.

Laboratory tests

• D‑dimer: Elevated in most acute thrombotic events; a normal level can safely exclude PE in low‑risk patients.
• Arterial blood gas (ABG): May reveal hypoxemia and respiratory alkalosis.
• Cardiac biomarkers (troponin, BNP): Elevated levels suggest right‑ventricular strain and higher mortality risk.

Clinical prediction rules

Tools such as the Wells score or the revised Geneva score stratify pre‑test probability. A high score combined with a positive D‑dimer or imaging confirms the diagnosis.

Treatment Options

Treatment aims to (1) stop clot propagation, (2) dissolve existing clots when appropriate, and (3) prevent recurrence.

Anticoagulation (first‑line)

• Low‑molecular‑weight heparin (LMWH): Enoxaparin 1 mg/kg subcutaneously every 12 h; preferred for its predictable pharmacokinetics.
• Unfractionated heparin (UFH):** Continuous IV infusion, titrated to aPTT 1.5‑2.5× control; useful in patients at high bleeding risk or needing rapid reversal.
• Direct oral anticoagulants (DOACs): Apixaban, rivaroxaban, edoxaban, or dabigatran are now first‑line for most uncomplicated PE (Cleveland Clinic, 2022).
• Duration: Minimum 3 months for provoked PE; indefinite for unprovoked or high‑risk cases.

Thrombolysis (for massive/high‑risk PE)

• Systemic thrombolytics: Alteplase 100 mg IV over 2 h. Indicated when hemodynamic collapse (shock) occurs.
• Catheter‑directed thrombolysis: Lower dose, delivered directly into the clot; reduces bleeding risk.
• Contraindications include active intracranial bleeding, recent major surgery, or uncontrolled hypertension.

Mechanical interventions

• Embolectomy: Surgical removal of clot, reserved for patients who fail thrombolysis or have absolute contraindications.
• Inferior vena cava (IVC) filter: Considered when anticoagulation is contraindicated; filters are retrieved when the risk resolves.

Supportive care

• Oxygen supplementation to maintain SpO₂ ≥ 94 %.
• Fluid management—avoid volume overload that can worsen right‑ventricular strain.
• Pain control with lightweight analgesics.

Living with Westermark’s Sign (Pulmonary Embolism Indicator)

Once a PE (and the associated Westermark’s sign) has been treated, ongoing self‑management is essential to prevent recurrence and maintain quality of life.

Medication adherence

• Take anticoagulants exactly as prescribed; missing doses can sharply increase clot risk.
• Set daily reminders or use pill‑organizer apps.
• If on a DOAC, take it with food as directed to improve absorption.

Monitoring

• Regular follow‑up labs (CBC, renal & liver function) for patients on warfarin or LMWH.
• Periodic imaging (e.g., duplex ultrasound) if you have known DVT.
• Watch for signs of bleeding: unusual bruising, hematuria, melena, or prolonged nosebleeds.

Lifestyle modifications

• Stay active: Aim for at least 150 minutes of moderate‑intensity aerobic activity per week (e.g., brisk walking).
• Leg elevation and gentle calf stretches during long periods of sitting.
• Maintain a healthy weight (BMI < 25 kg/m²).
• Quit smoking; tobacco increases clotting tendency and impairs lung function.
• Stay hydrated, especially during travel or hot weather.

Psychosocial wellbeing

PE can be frightening. Consider joining a support group or speaking with a mental‑health professional to manage anxiety or post‑PE stress disorder (PPESD).

Prevention

Primary prevention targets the same risk factors that cause PE.

• Compression stockings: Graduated stockings (15‑30 mmHg) for postoperative patients or those with chronic venous insufficiency.
• Pharmacologic prophylaxis: Low‑dose LMWH, fondaparinux, or DOAC prophylaxis for high‑risk surgical patients.
• Early ambulation: Get up and move within 24 h after surgery whenever possible.
• Hydration: Adequate fluid intake reduces blood viscosity.
• Pregnancy & postpartum care: Use anticoagulation if you have additional risk factors (e.g., thrombophilia).
• Routine screening: For people with known thrombophilia, periodic assessment and possibly prophylactic anticoagulation during high‑risk periods (long travel, surgery).

Complications

If a PE presenting with Westermark’s sign is missed or inadequately treated, serious complications can develop.

• Right‑ventricular (RV) failure: Sudden increase in pulmonary artery pressure strains the RV, leading to cardiogenic shock.
• Chronic thromboembolic pulmonary hypertension (CTEPH): Persistent obstruction causes long‑term hypertension, dyspnea, and reduced exercise capacity.
• Recurrent PE: Risk rises without proper anticoagulation.
• Bleeding complications: Paradoxically, over‑aggressive anticoagulation can cause major hemorrhage.
• Mortality: Unrecognized massive PE carries a 30‑day mortality > 25 % (NEJM, 2018).

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you experience any of the following:

• Sudden, severe shortness of breath that worsens rapidly.
• Chest pain that feels sharp, worsens with breathing, or is associated with a feeling of “pressure.”
• Fainting, severe dizziness, or a feeling that you might pass out.
• Rapid, irregular heartbeat (palpitations) or a heart rate > 120 bpm.
• Leg swelling accompanied by redness or warmth, especially if you also have shortness of breath.
• Visible coughing up blood (hemoptysis).
• Sudden collapse or weakness in one side of the body (possible concurrent stroke).

These symptoms may signal a massive or sub‑massive pulmonary embolism, a life‑threatening emergency that requires rapid assessment, possible thrombolysis, and intensive supportive care.

References

• Centers for Disease Control and Prevention. “Data & Statistics on Venous Thromboembolism.” 2022. cdc.gov
• Mayo Clinic. “CT Pulmonary Angiography.” 2023. mayo.org
• Cleveland Clinic. “Pulmonary Embolism.” 2022. clevelandclinic.org
• Wells PS, et al. “Evaluation of D-dimer in the Diagnosis of Pulmonary Embolism.” New England Journal of Medicine. 2018.
• Radiology. “Westermark’s Sign – Frequency and Clinical Relevance.” 2017. doi.org
• World Health Organization. “Guidelines on Prevention and Management of Venous Thromboembolism.” 2021.

```